Know Global Oncology Trend Report 2015 : Developments in Cancer Treatments, Market Dynamics, Patient Access and Value

VIDEO: Innovative treatments, often combined with other new or existing medicines. Watch video below

Key Findings

Global oncology spending reaches $100 billion in 2014

The report found that total global spending on oncology medicines – including therapeutic treatments and supportive care – reached the $100 billion threshold in 2014, even as the share of total medicine spending of oncologics increased only modestly.

Growth in global spending on cancer drugs – measured using ex-manufacturer prices and not reflecting off-invoice discounts, rebates or patient access programs – increased at a compound annual growth rate (CAGR) of 6.5 percent on a constant-dollar basis during the past five years.
Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer care.

In most instances, five-year survival rates have risen through continuous and small improvements in detection and treatment – including refinements with existing treatments and gains from new treatment options.Survival rates have steadily improved over the past 20 years

Assessment of value for oncology products is becoming more complex as most products have multiple indications

By 2020, most oncology drugs will carry multiple indications, reflecting developers’pursuit of genetic targets across multiple tumors, and the rise of immuno- oncologics,which may have more than six indications
Of 88 cancer drugs marketed in 2014, 40 were for single indications and 48 for multiple indications.